2022 Q4 Form 10-Q Financial Statement
#000165495422015282 Filed on November 14, 2022
Income Statement
Concept | 2022 Q4 | 2022 Q3 | 2021 Q3 |
---|---|---|---|
Revenue | $1.026M | $869.7K | $159.5K |
YoY Change | 310.57% | 445.3% | -155.27% |
Cost Of Revenue | $98.71K | $86.50K | $53.93K |
YoY Change | 238.38% | 60.39% | 114.01% |
Gross Profit | $927.7K | $783.2K | $105.6K |
YoY Change | 320.1% | 641.97% | -133.64% |
Gross Profit Margin | 90.38% | 90.05% | 66.18% |
Selling, General & Admin | $3.174M | $3.509M | $3.837M |
YoY Change | -4.32% | -8.54% | 64.55% |
% of Gross Profit | 342.17% | 448.04% | 3634.81% |
Research & Development | $4.368M | $6.027M | $3.485M |
YoY Change | -19.51% | 72.95% | 19.18% |
% of Gross Profit | 470.79% | 769.59% | 3301.53% |
Depreciation & Amortization | $69.77K | $59.63K | $12.56K |
YoY Change | 152.88% | 374.76% | -6.58% |
% of Gross Profit | 7.52% | 7.61% | 11.9% |
Operating Expenses | $6.613M | $9.622M | $7.375M |
YoY Change | -24.62% | 30.47% | 101.68% |
Operating Profit | -$5.587M | -$8.753M | -$7.216M |
YoY Change | -33.89% | 21.3% | 82.89% |
Interest Expense | $5.487K | $9.602K | $5.631K |
YoY Change | 97.87% | 70.52% | -24.81% |
% of Operating Profit | |||
Other Income/Expense, Net | -$512.2K | $497.3K | $103.1K |
YoY Change | 117.71% | 382.13% | 2119.93% |
Pretax Income | -$6.099M | -$8.255M | -$7.113M |
YoY Change | -29.79% | 16.07% | 80.49% |
Income Tax | -$4.675M | ||
% Of Pretax Income | |||
Net Earnings | -$1.424M | -$8.255M | -$7.113M |
YoY Change | -83.61% | 16.07% | 80.49% |
Net Earnings / Revenue | -138.74% | -949.28% | -4459.88% |
Basic Earnings Per Share | |||
Diluted Earnings Per Share | -$0.13 | -$856.8K | -$29.86K |
COMMON SHARES | |||
Basic Shares Outstanding | 10.35M shares | 9.290M shares | |
Diluted Shares Outstanding |
Balance Sheet
Concept | 2022 Q4 | 2022 Q3 | 2021 Q3 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $21.18M | $21.19M | $53.42M |
YoY Change | -55.24% | -60.33% | -38.3% |
Cash & Equivalents | $21.18M | $21.19M | $53.42M |
Short-Term Investments | |||
Other Short-Term Assets | $2.127M | $2.105M | $2.947M |
YoY Change | -10.61% | -28.57% | 24.86% |
Inventory | $759.3K | $858.0K | $1.108M |
Prepaid Expenses | |||
Receivables | $1.807M | $2.023M | $914.0K |
Other Receivables | $4.675M | $0.00 | $0.00 |
Total Short-Term Assets | $30.55M | $26.18M | $58.39M |
YoY Change | -40.52% | -55.17% | -41.48% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $674.6K | $620.9K | $140.0K |
YoY Change | 31.93% | 343.44% | -89.37% |
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | $56.92K | $56.92K | $56.92K |
YoY Change | 0.0% | 0.0% | -0.01% |
Total Long-Term Assets | $1.425M | $1.465M | $1.343M |
YoY Change | -12.37% | 9.03% | -2.24% |
TOTAL ASSETS | |||
Total Short-Term Assets | $30.55M | $26.18M | $58.39M |
Total Long-Term Assets | $1.425M | $1.465M | $1.343M |
Total Assets | $31.98M | $27.64M | $59.73M |
YoY Change | -39.66% | -53.72% | -40.95% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $820.3K | $3.774M | $762.8K |
YoY Change | 412.11% | 394.8% | -21.47% |
Accrued Expenses | $6.066M | $6.117M | $4.991M |
YoY Change | -1.82% | 22.55% | 21.56% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | $103.6K | $102.3K | |
YoY Change | 6.91% | ||
Total Short-Term Liabilities | $11.42M | $15.86M | $9.788M |
YoY Change | -17.63% | 62.05% | -22.64% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $99.91K | $126.3K | $0.00 |
YoY Change | -51.24% | ||
Other Long-Term Liabilities | $3.733M | $2.740M | $6.168M |
YoY Change | 23.87% | -55.57% | -46.51% |
Total Long-Term Liabilities | $3.733M | $2.740M | $6.168M |
YoY Change | 23.87% | -55.57% | -46.51% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $11.42M | $15.86M | $9.788M |
Total Long-Term Liabilities | $3.733M | $2.740M | $6.168M |
Total Liabilities | $15.63M | $19.19M | $16.76M |
YoY Change | -12.17% | 14.49% | -30.68% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$397.7M | -$396.2M | -$358.9M |
YoY Change | 8.18% | 10.4% | |
Common Stock | $103.5K | $92.91K | $2.313M |
YoY Change | -95.53% | -95.98% | |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $16.34M | $8.449M | $42.97M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $31.98M | $27.64M | $59.73M |
YoY Change | -39.66% | -53.72% | -40.95% |
Cashflow Statement
Concept | 2022 Q4 | 2022 Q3 | 2021 Q3 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$1.424M | -$8.255M | -$7.113M |
YoY Change | -83.61% | 16.07% | 80.49% |
Depreciation, Depletion And Amortization | $69.77K | $59.63K | $12.56K |
YoY Change | 152.88% | 374.76% | -6.58% |
Cash From Operating Activities | -$8.824M | -$24.73K | -$6.424M |
YoY Change | 40.31% | -99.61% | -268.47% |
INVESTING ACTIVITIES | |||
Capital Expenditures | $123.4K | -$141.2K | -$57.76K |
YoY Change | -238.53% | 144.51% | |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | |||
YoY Change | |||
Cash From Investing Activities | -$123.4K | -$141.2K | -$57.76K |
YoY Change | 38.53% | 144.49% | |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 8.938M | -$8.581M | -$202.4K |
YoY Change | 3066.69% | 4140.77% | 160.21% |
NET CHANGE | |||
Cash From Operating Activities | -8.824M | -$24.73K | -$6.424M |
Cash From Investing Activities | -123.4K | -$141.2K | -$57.76K |
Cash From Financing Activities | 8.938M | -$8.581M | -$202.4K |
Net Change In Cash | -9.040K | -$8.747M | -$6.684M |
YoY Change | -99.85% | 30.87% | -278.94% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$8.824M | -$24.73K | -$6.424M |
Capital Expenditures | $123.4K | -$141.2K | -$57.76K |
Free Cash Flow | -$8.947M | $116.5K | -$6.366M |
YoY Change | 44.31% | -101.83% | -266.95% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2022Q3 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
260957 | usd |
CY2021Q3 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
398812 | usd |
CY2022Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
CY2022Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
4030 | shares |
CY2022Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
CY2022Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
300000000 | shares |
CY2022Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
9290504 | shares |
CY2022Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
9270947 | shares |
CY2022Q3 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
86496 | usd |
CY2021Q3 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
53933 | usd |
CY2022Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
6027031 | usd |
CY2021Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3484764 | usd |
CY2022Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3508798 | usd |
CY2021Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3836542 | usd |
CY2022Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
497263 | usd |
CY2021Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
103138 | usd |
CY2022Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8255408 | usd |
CY2021Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-7112619 | usd |
CY2022Q3 | ptn |
Basic And Diluted Net Loss Per Common Share
BasicAndDilutedNetLossPerCommonShare
|
86 | shares |
CY2021Q3 | ptn |
Basic And Diluted Net Loss Per Common Share
BasicAndDilutedNetLossPerCommonShare
|
75 | shares |
CY2022Q3 | ptn |
Weighted Average Number Of Common Shares Outstanding Used In Computing Basic And Diluted Net Loss Per Common Share Note1
WeightedAverageNumberOfCommonSharesOutstandingUsedInComputingBasicAndDilutedNetLossPerCommonShareNote1
|
9634684 | |
CY2021Q3 | ptn |
Weighted Average Number Of Common Shares Outstanding Used In Computing Basic And Diluted Net Loss Per Common Share Note1
WeightedAverageNumberOfCommonSharesOutstandingUsedInComputingBasicAndDilutedNetLossPerCommonShareNote1
|
9529322 | |
CY2022Q3 | ptn |
Profits Loss
ProfitsLoss
|
8255408 | usd |
CY2021Q3 | ptn |
Profits Loss
ProfitsLoss
|
7112619 | usd |
CY2022Q3 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
59625 | usd |
CY2021Q3 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
12559 | usd |
CY2021Q3 | ptn |
Decrease In Right Of Use Asset
DecreaseInRightOfUseAsset
|
91481 | usd |
CY2022Q3 | ptn |
Unrealized Foreign Currency Transaction Gain Loss
UnrealizedForeignCurrencyTransactionGainLoss
|
418376 | usd |
CY2021Q3 | ptn |
Unrealized Foreign Currency Transaction Gain Loss
UnrealizedForeignCurrencyTransactionGainLoss
|
107359 | usd |
CY2022Q3 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
436877 | usd |
CY2021Q3 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
632727 | usd |
CY2022Q3 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-242730 | usd |
CY2021Q3 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
666428 | usd |
CY2022Q3 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-172401 | usd |
CY2021Q3 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
112882 | usd |
CY2022Q3 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
86496 | usd |
CY2022Q3 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
682920 | usd |
CY2021Q3 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
122167 | usd |
CY2022Q3 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-758375 | usd |
CY2021Q3 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-806214 | usd |
CY2022Q3 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-91682 | usd |
CY2021Q3 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-89608 | usd |
CY2022Q3 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-8581320 | usd |
CY2021Q3 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-6423623 | usd |
CY2021Q3 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-57764 | usd |
CY2022Q3 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-141228 | usd |
CY2022Q3 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
0 | usd |
CY2021Q3 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
202353 | usd |
CY2022Q3 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
24731 | usd |
CY2021Q3 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
0 | usd |
CY2022Q3 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-24731 | usd |
CY2021Q3 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-202353 | usd |
CY2022Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-8747279 | usd |
CY2021Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-6683740 | usd |
CY2022Q3 | us-gaap |
Interest Paid Net
InterestPaidNet
|
9602 | usd |
CY2021Q3 | us-gaap |
Interest Paid Net
InterestPaidNet
|
5631 | usd |
CY2022Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-396249104 | usd |
CY2022Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8255408 | usd |
CY2022Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
21191875 | usd |
CY2022Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
15861001 | usd |
CY2022Q3 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
21057025 | usd |
CY2021Q2 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
29740565 | usd |
CY2022Q2 | ptn |
Vyleesi Contractual Advances
VyleesiContractualAdvances
|
815750 | usd |
CY2022Q2 | ptn |
Prepaid Clinical Study Costs
PrepaidClinicalStudyCosts
|
310573 | usd |
CY2020Q3 | ptn |
Contract Termination Agreement Payments
ContractTerminationAgreementPayments
|
12000000 | usd |
CY2021Q1 | ptn |
Contract Termination Agreement Payments
ContractTerminationAgreementPayments
|
4300000 | usd |
CY2022Q3 | us-gaap |
Related Party Transaction Purchases From Related Party
RelatedPartyTransactionPurchasesFromRelatedParty
|
18194000 | usd |
CY2022Q3 | us-gaap |
Line Of Credit Facility Increase Accrued Interest
LineOfCreditFacilityIncreaseAccruedInterest
|
2300000 | usd |
CY2020Q3 | ptn |
Inventory And Prepaid Expenses Estimated Fair Value
InventoryAndPrepaidExpensesEstimatedFairValue
|
5817795 | usd |
CY2020Q3 | ptn |
Gain On License Termination Agreement
GainOnLicenseTerminationAgreement
|
1623795 | usd |
CY2021Q2 | us-gaap |
Loss On Contract Termination
LossOnContractTermination
|
4407987 | usd |
CY2021Q2 | ptn |
Net Loss
NetLoss
|
2784192 | usd |
CY2022Q2 | ptn |
Prepaid Insurance Premiums
PrepaidInsurancePremiums
|
132413 | usd |
CY2022Q3 | ptn |
Agreement With Fosun
AgreementWithFosun
|
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong>(7) AGREEMENT WITH FOSUN</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On September 6, 2017, the Company entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (“Fosun”) for exclusive rights to commercialize Vyleesi in China (the “Fosun License Agreement”). Under the terms of the agreement, the Company received $4,500,000 in October 2017, which consisted of an upfront payment of $5,000,000 less $500,000 that was withheld in accordance with tax withholding requirements in China and recorded as an expense during the year ended June 30, 2018. The Company is entitled to receive a $7,500,000 milestone payment when regulatory approval in China is obtained, provided that a commercial supply agreement for Vyleesi has been entered into. The Company has the potential to receive up to $92,500,000 in additional sales related milestone payments and high single-digit to low double-digit royalties on net sales in the licensed territory. All development, regulatory, sales, marketing, and commercial activities and associated costs in the licensed territory will be the sole responsibility of Fosun. </p> | |
CY2017Q3 | us-gaap |
Increase Decrease In Deferred Revenue And Customer Advances And Deposits
IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits
|
4500000 | usd |
CY2017Q3 | us-gaap |
Payments For Restructuring
PaymentsForRestructuring
|
5000000 | usd |
CY2017Q3 | ptn |
Taxexpenses
taxexpenses
|
500000 | usd |
CY2017Q3 | us-gaap |
Payments To Acquire Receivables
PaymentsToAcquireReceivables
|
7500000 | usd |
CY2017Q3 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
|
92500000 | usd |
CY2017Q4 | us-gaap |
Officers Compensation
OfficersCompensation
|
417500 | usd |
CY2017Q4 | us-gaap |
Payments For Restructuring
PaymentsForRestructuring
|
500000 | usd |
CY2017Q4 | ptn |
Taxexpenses
taxexpenses
|
82500 | usd |
CY2017Q4 | us-gaap |
Payments To Acquire Receivables
PaymentsToAcquireReceivables
|
3000000 | usd |
CY2017Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
|
37500000 | usd |
CY2022Q2 | us-gaap |
Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
|
1932454 | usd |
CY2022Q2 | us-gaap |
Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
|
29740565 | usd |
CY2022Q2 | ptn |
Clinical Study Costs
ClinicalStudyCosts
|
3944798 | usd |
CY2022Q2 | ptn |
Other Research Related Expenses
OtherResearchRelatedExpenses
|
35172 | usd |
CY2022Q2 | ptn |
Personal Cost
PersonalCost
|
1545896 | usd |
CY2022Q2 | ptn |
Accrued Selling Expenses
AccruedSellingExpenses
|
840703 | usd |
CY2022Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
157390 | usd |
CY2022Q2 | ptn |
Tota Acrrued Liabilities
TotaAcrruedLiabilities
|
6875216 | usd |
CY2022Q3 | us-gaap |
Advances On Inventory Purchases
AdvancesOnInventoryPurchases
|
9125648 | usd |
CY2022Q2 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
5754986 | usd |
CY2022Q2 | ptn |
Accrued Other Long Term Liabilities
AccruedOtherLongTermLiabilities
|
2861250 | usd |
CY2022Q3 | ptn |
Voting Of Shares Description
VotingOfSharesDescription
|
The holders of Series C Preferred Stock were entitled to 20,000 votes per share of common stock | |
CY2022Q3 | ptn |
Number Of Shares Issued
NumberOfSharesIssued
|
40000000 | shares |
CY2022Q3 | ptn |
Decription Of Commission
DecriptionOfCommission
|
The Company pays Canaccord 3.0% of the gross proceeds as a commission | |
CY2022Q3 | ptn |
Shares Of Common Stock
SharesOfCommonStock
|
33333 | shares |
CY2022Q3 | us-gaap |
Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
|
33333 | shares |
CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
|
P7Y1M6D | |
CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1660 | shares |
CY2022Q3 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
6.36 | |
CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
4768 | shares |
CY2022Q3 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
12.17 | |
CY2022Q3 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0 | |
CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
17056 | shares |
CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
18.00 | |
CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1143798 | shares |
CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
15.95 | |
CY2022Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y10M24D | |
CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
685855 | shares |
CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
18.34 | |
CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
457943 | shares |
CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
12.38 | |
CY2022Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P8Y9M18D | |
CY2022Q3 | ptn |
Unvested Performance Based Stock Options Granted To Executive Officers And Other Employees
UnvestedPerformanceBasedStockOptionsGrantedToExecutiveOfficersAndOtherEmployees
|
166233 | shares |
CY2022Q3 | ptn |
Unvested Performance Based Stock Options Granted
UnvestedPerformanceBasedStockOptionsGranted
|
18921 | shares |
CY2020Q2 | ptn |
Unvested Performances Based Restricted Stock Unit
UnvestedPerformancesBasedRestrictedStockUnit
|
87303 | usd |
CY2021Q2 | ptn |
Unvested Performances Based Restricted Stock Unit
UnvestedPerformancesBasedRestrictedStockUnit
|
95167 | usd |
CY2021Q3 | us-gaap |
Restricted Stock Expense
RestrictedStockExpense
|
233915 | usd |
CY2021Q2 | ptn |
Performance Based Restricted Stock
PerformanceBasedRestrictedStock
|
18000 | shares |
CY2022Q3 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0000911216 | |
CY2022Q3 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2022Q3 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--06-30 | |
CY2022Q3 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
CY2022Q3 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2023 | |
CY2022Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.01 | |
CY2022Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
CY2022Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
4030 | shares |
CY2022Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
4030 | shares |
CY2022Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
CY2022Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
300000000 | shares |
CY2022Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
9270947 | shares |
CY2022Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
9290504 | shares |
CY2022Q2 | us-gaap |
Related Party Transaction Purchases From Related Party
RelatedPartyTransactionPurchasesFromRelatedParty
|
1623795 | usd |
CY2022Q3 | ptn |
License And Contract Revenue
LicenseAndContractRevenue
|
2500000 | usd |
CY2017Q4 | ptn |
License Agreement
LicenseAgreement
|
94869 | usd |
CY2022Q2 | us-gaap |
Contributions In Aid Of Construction
ContributionsInAidOfConstruction
|
220864 | usd |
CY2022Q3 | us-gaap |
Contributions In Aid Of Construction
ContributionsInAidOfConstruction
|
168210 | usd |
CY2022Q3 | dei |
Document Type
DocumentType
|
10-Q | |
CY2022Q3 | dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | |
CY2022Q3 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2022-09-30 | |
CY2022Q3 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
CY2022Q3 | dei |
Entity File Number
EntityFileNumber
|
001-15543 | |
CY2022Q3 | dei |
Entity Registrant Name
EntityRegistrantName
|
PALATIN TECHNOLOGIES, INC. | |
CY2022Q3 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | |
CY2022Q3 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
95-4078884 | |
CY2022Q3 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
4B Cedar Brook Drive | |
CY2022Q3 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Cranbury | |
CY2022Q3 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
NJ | |
CY2022Q3 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
08512 | |
CY2022Q3 | dei |
City Area Code
CityAreaCode
|
609 | |
CY2022Q3 | dei |
Local Phone Number
LocalPhoneNumber
|
495‑2200 | |
CY2022Q3 | dei |
Security12b Title
Security12bTitle
|
Common Stock, par value $0.01 per share | |
CY2022Q3 | dei |
Trading Symbol
TradingSymbol
|
PTN | |
CY2022Q3 | dei |
Security Exchange Name
SecurityExchangeName
|
NYSEAMER | |
CY2022Q3 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2022Q3 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
CY2022Q3 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
CY2022Q3 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
CY2022Q3 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
CY2022Q3 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
CY2022Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
10353926 | shares |
CY2022Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
21191875 | usd |
CY2022Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
29939154 | usd |
CY2022Q3 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
2022750 | usd |
CY2022Q2 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
1780020 | usd |
CY2022Q3 | us-gaap |
Inventory Net
InventoryNet
|
857975 | usd |
CY2022Q2 | us-gaap |
Inventory Net
InventoryNet
|
944471 | usd |
CY2022Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2104855 | usd |
CY2022Q2 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1932454 | usd |
CY2022Q3 | us-gaap |
Assets Current
AssetsCurrent
|
26177455 | usd |
CY2022Q2 | us-gaap |
Assets Current
AssetsCurrent
|
34596099 | usd |
CY2022Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
620917 | usd |
CY2022Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
539314 | usd |
CY2022Q3 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
786731 | usd |
CY2022Q2 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
878465 | usd |
CY2022Q3 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
56916 | usd |
CY2022Q2 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
56916 | usd |
CY2022Q3 | us-gaap |
Assets
Assets
|
27642019 | usd |
CY2022Q2 | us-gaap |
Assets
Assets
|
36070794 | usd |
CY2022Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3774399 | usd |
CY2022Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3157617 | usd |
CY2022Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
6116841 | usd |
CY2022Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
6875216 | usd |
CY2022Q3 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
343749 | usd |
CY2022Q2 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
371124 | usd |
CY2022Q3 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
102264 | usd |
CY2022Q2 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
100921 | usd |
CY2022Q3 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
5523748 | usd |
CY2022Q2 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
5754986 | usd |
CY2022Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
15861001 | usd |
CY2022Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
16259864 | usd |
CY2022Q3 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
465091 | usd |
CY2022Q2 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
529398 | usd |
CY2022Q3 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
126333 | usd |
CY2022Q2 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
152407 | usd |
CY2022Q3 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
2740250 | usd |
CY2022Q2 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
2861250 | usd |
CY2022Q3 | us-gaap |
Liabilities
Liabilities
|
19192675 | usd |
CY2022Q2 | us-gaap |
Liabilities
Liabilities
|
19802919 | usd |
CY2022Q3 | ptn |
Escrowed Proceeds
EscrowedProceeds
|
-15000000 | usd |
CY2022Q2 | ptn |
Escrowed Proceeds
EscrowedProceeds
|
-15000000 | usd |
CY2022Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.01 | |
CY2022Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
4030 | shares |
CY2022Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
40 | usd |
CY2022Q2 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
40 | usd |
CY2022Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
92905 | usd |
CY2022Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
92709 | usd |
CY2022Q3 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
404605503 | usd |
CY2022Q2 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
404168822 | usd |
CY2022Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-396249104 | usd |
CY2022Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-387993696 | usd |
CY2022Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
8449344 | usd |
CY2022Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
16267875 | usd |
CY2022Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
27642019 | usd |
CY2022Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
36070794 | usd |
CY2022Q3 | ptn |
Product Revenue Net
ProductRevenueNet
|
869654 | usd |
CY2021Q3 | ptn |
Product Revenue Net
ProductRevenueNet
|
159482 | usd |
CY2022Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
9622325 | usd |
CY2021Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
7375239 | usd |
CY2022Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-8752671 | usd |
CY2021Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-7215757 | usd |
CY2022Q3 | us-gaap |
Investment Income Net
InvestmentIncomeNet
|
88489 | usd |
CY2021Q3 | us-gaap |
Investment Income Net
InvestmentIncomeNet
|
1410 | usd |
CY2022Q3 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
418376 | usd |
CY2021Q3 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
107359 | usd |
CY2022Q3 | us-gaap |
Interest Expense
InterestExpense
|
9602 | usd |
CY2021Q3 | us-gaap |
Interest Expense
InterestExpense
|
5631 | usd |
CY2022Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
16267875 | usd |
CY2022Q3 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
436877 | usd |
CY2022Q3 | ptn |
Reverse Stock Split Fractional Shares Amount
ReverseStockSplitFractionalSharesAmount
|
0 | usd |
CY2022Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8255408 | usd |
CY2022Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
8449344 | usd |
CY2021Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
49651372 | usd |
CY2021Q3 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
632727 | usd |
CY2021Q3 | ptn |
Taxes Withheld Related To Restricted Stock Units Amount
TaxesWithheldRelatedToRestrictedStockUnitsAmount
|
-202353 | usd |
CY2021Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-7112619 | usd |
CY2021Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
42969127 | usd |
CY2022Q3 | ptn |
Decrease In Right Of Use Asset
DecreaseInRightOfUseAsset
|
91734 | usd |
CY2021Q3 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
53933 | usd |
CY2022Q3 | ptn |
Purchases Of Property And Equipment
PurchasesOfPropertyAndEquipment
|
141228 | usd |
CY2021Q3 | ptn |
Purchases Of Property And Equipment
PurchasesOfPropertyAndEquipment
|
57764 | usd |
CY2022Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
29939154 | usd |
CY2021Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
60104919 | usd |
CY2022Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
21191875 | usd |
CY2021Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
53421179 | usd |
CY2022Q3 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>Use of Estimates</em> – The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> | |
CY2022Q3 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
2690259 | usd |
CY2021Q3 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
2630634 | usd |
CY2022Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
2829183 | shares |
CY2021Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
1317262 | shares |
CY2022Q3 | us-gaap |
Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
|
344180 | shares |
CY2021Q3 | us-gaap |
Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
|
269365 | shares |
CY2022Q3 | ptn |
Prepaid Clinical Study Costs
PrepaidClinicalStudyCosts
|
446189 | usd |
CY2022Q3 | ptn |
Prepaid Insurance Premiums
PrepaidInsurancePremiums
|
121000 | usd |
CY2022Q3 | ptn |
Vyleesi Contractual Advances
VyleesiContractualAdvances
|
815750 | usd |
CY2022Q3 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
721916 | usd |
CY2022Q2 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
673718 | usd |
CY2022Q3 | us-gaap |
Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
|
2104855 | usd |
CY2022Q3 | us-gaap |
Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
|
21057025 | usd |
CY2022Q3 | ptn |
Clinical Study Costs
ClinicalStudyCosts
|
4810130 | usd |
CY2022Q3 | ptn |
Other Research Related Expenses
OtherResearchRelatedExpenses
|
255754 | usd |
CY2022Q3 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
129009 | usd |
CY2022Q2 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
351257 | usd |
CY2022Q3 | ptn |
Personal Cost
PersonalCost
|
0 | usd |
CY2022Q3 | ptn |
Accrued Selling Expenses
AccruedSellingExpenses
|
692968 | usd |
CY2022Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
228980 | usd |
CY2022Q3 | ptn |
Tota Acrrued Liabilities
TotaAcrruedLiabilities
|
6116841 | usd |
CY2022Q3 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
5523748 | usd |
CY2022Q3 | ptn |
Accrued Other Long Term Liabilities
AccruedOtherLongTermLiabilities
|
2740250 | usd |
CY2022Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1163962 | shares |
CY2022Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
15.98 | |
CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
875 | usd |
CY2022Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P5Y8M12D | |
CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
875 | usd |
CY2022Q2 | ptn |
Unvested Performances Based Restricted Stock Unit
UnvestedPerformancesBasedRestrictedStockUnit
|
60566 | usd |
CY2022Q3 | us-gaap |
Restricted Stock Expense
RestrictedStockExpense
|
175920 | usd |
CY2022Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
|
649149 | shares |
CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
|
2608 | shares |
CY2022Q3 | ptn |
Restricted Stock Vested In Period
RestrictedStockVestedInPeriod
|
-19600 | shares |
CY2022Q3 | ptn |
Fractional Shares
FractionalShares
|
-6 | shares |
CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
|
626935 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
|
1020000 | usd |
CY2022Q4 | ptn |
Pre Funded Warrants
PreFundedWarrants
|
798182 | shares |
CY2022Q4 | ptn |
Purchase Of Common Stock
PurchaseOfCommonStock
|
1818182 | shares |
CY2022Q4 | us-gaap |
Share Price
SharePrice
|
5.50 | |
CY2022Q4 | ptn |
Combined Offering Price
CombinedOfferingPrice
|
5.4999 | |
CY2022Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
5.83 | |
CY2022Q4 | ptn |
Pre Funded Warrants Exercise Price
PreFundedWarrantsExercisePrice
|
0.0001 | |
CY2022Q4 | us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
9100000 | usd |
CY2022Q4 | us-gaap |
Line Of Credit Facility Commitment Fee Percentage
LineOfCreditFacilityCommitmentFeePercentage
|
0.0499 | pure |
CY2022Q4 | ptn |
Description Of Shareholder Ownership
DescriptionOfShareholderOwnership
|
any holder may increase or decrease such percentage to any other percentage not in excess of 9.99% upon notice to us, provided that any increase in this limitation will not be effective until 61 days after such notice from the holder to the Company |